The Zacks Analyst Blog Highlights JPMorgan Chase, UnitedHealth, Verizon, Twin Disc and Sypris

17.12.24 10:46 Uhr

Werte in diesem Artikel
Aktien

227,00 EUR -1,35 EUR -0,59%

11,40 EUR 0,00 EUR 0,00%

472,35 EUR -4,05 EUR -0,85%

38,86 EUR -0,61 EUR -1,55%

Indizes

PKT PKT

43.717,5 PKT -110,6 PKT -0,25%

16.792,5 PKT -32,7 PKT -0,19%

2.977,7 PKT 19,1 PKT 0,64%

6.074,1 PKT 23,0 PKT 0,38%

For Immediate ReleaseChicago, IL – December 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, UnitedHealth Group Inc. UNH, Verizon Communications Inc. VZ, Twin Disc, Inc. TWIN and Sypris Solutions, Inc. SYPR.Here are highlights from Monday’s Analyst Blog:Top Research Reports for JPMorgan, UnitedHealth and VerizonThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., UnitedHealth Group Inc. and Verizon Communications Inc., as well as two micro-cap stocks Twin Disc, Inc. and Sypris Solutions, Inc. The Zacks microcap research is unique as our reseaarch content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Shares of JPMorgan Chase have outperformed the Zacks Finance sector this year (+41% vs. +21%) as well as the S&P 500 index (+41% vs. +27.8%). Driving the momentum is the company's leverage to the steadily improving macroeconomic backdrop, characterized by optimism about the incoming administration's policy agenda and the ongoing monetary easing program.According to the Zacks analyst estimates NII (managed) and total loans imply a CAGR of 1.2% and 5.2%, respectively, by 2026. A resurgence in deal-making activities and the company’s leading position in the investment banking (IB) business are expected to aid related fee income.Yet, the volatile nature of the capital markets business and high mortgage rates will likely hurt fee income growth. Owing to these challenges, we expect non-interest income (managed) to rise in 2024 but decline next year. Mounting operating expenses will hamper the bottom line. We expect non-interest expenses to rise 5.5% in 2024.(You can read the full research report on JPMorgan Chase here >>>)UnitedHealth Group shares have modestly outperformed the Zacks Medical - HMOs industry over the past year (+1.3% vs. -3.8%), though the stock has been under pressure lately following the tragic headlines about its senior executive's murder in New York. The company’s top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. The company’s solid health services segment provides diversification benefits.The Government business remains well-poised for growth in the future. Adjusted net earnings per share are anticipated to be in the $27.5-$27.75 band in 2024. A sturdy balance sheet enables investments and prudent deployment of capital via share repurchases and dividend payments.However, membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. A debt-laden balance sheet induces an increase in interest expenses. As such, the stock warrants a cautious stance.(You can read the full research report on UnitedHealth here >>>)Shares of Verizon have gained +20.3% over the past year against the Zacks Wireless National industry’s gain of +40.4%. The company is witnessing significant 5G adoption and fixed wireless broadband momentum. Its 5G mobility service offers a premium experience across various industries such as public safety, health care, retail and more.Verizon’s mmWave footprint delivers game changing experiences for the densest parts of the network and offers highly predictable signal waves leading to greater efficiency and less interference for customers. The company’s focus on online content delivery, mobile video and online advertising is expected to drive growth.However, stiff competition from other major players and saturation in the U.S. wireless market is hurting its profits. Heavy spending on promotional activities to attract customers is straining margins. A challenging macroeconomic environment and lower postpaid phone upgrades are major concerns.(You can read the full research report on Verizon here >>>)Twin Disc’s shares have underperformed the Zacks Manufacturing - General Industrial industry over the past year (-12.1% vs. +19.7%). This microcap company with market capitalization of $171.8 million is witnessing rising debt from Katsa's acquisition and increased financial leverage, while declining land-based sales reflect sector-specific weaknesses. Currency volatility, geopolitical risks, and competitive pressures in electrification pose additional challenges.However, Twin Disc's investment thesis centers on strong backlog growth, product diversity, and strategic initiatives in hybrid and electrification technologies. The six-month backlog reached $144.3 million in the first quarter of fiscal 2025 (up 17.8% year over year), reflecting robust demand across marine, industrial, and land-based applications, with Veth propulsion orders up 19%.Marine & Propulsion Systems sales rose 22.9% year over year, supported by global defense spending and luxury yacht adoption. The Katsa Oy acquisition expanded Twin Disc's European reach. Geographic diversification and a balanced product mix mitigate regional risks.(You can read the full research report on Twin Disc here >>>)Shares of Sypris Solutions have underperformed the Zacks Electronics - Miscellaneous Services industry over the past year (-18.2% vs. +10.3%). This microcap company with market capitalization of $36.15 million is facing liquidity challenges and elevated debt obligations constrain financial flexibility. Rising costs and reliance on cyclical markets such as heavy vehicles and oil and gas exacerbate margin sensitivity.Nevertheless, Sypris Solutions benefits from an extended long-term supply agreement with a global OEM, securing stable revenue as a sole-source supplier of Ultra Axle Shafts. The company’s diversified presence across automotive, energy, and industrial markets reduces risk and positions it to capitalize on growth trends in heavy-duty vehicles and energy infrastructure.Sypris Solutions is also aligned with growth in aerospace and defense electronics, leveraging its capabilities in high-precision components. Global infrastructure initiatives drive demand for its drivetrain products. Expansion into the Asia-Pacific region aligns with high-growth markets, leveraging regional investments in defense and infrastructure.(You can read the full research report on Sypris Solutions here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Twin Disc, Incorporated (TWIN): Free Stock Analysis Report Sypris Solutions, Inc. (SYPR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Chase

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Chase

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu UnitedHealth Inc.

Analysen zu UnitedHealth Inc.

DatumRatingAnalyst
14.04.2022UnitedHealth OutperformRBC Capital Markets
15.10.2020UnitedHealth OutperformCredit Suisse Group
14.10.2020UnitedHealth OutperformRBC Capital Markets
29.08.2019UnitedHealth OutperformCredit Suisse Group
17.07.2018UnitedHealth buyGoldman Sachs Group Inc.
DatumRatingAnalyst
14.04.2022UnitedHealth OutperformRBC Capital Markets
15.10.2020UnitedHealth OutperformCredit Suisse Group
14.10.2020UnitedHealth OutperformRBC Capital Markets
29.08.2019UnitedHealth OutperformCredit Suisse Group
17.07.2018UnitedHealth buyGoldman Sachs Group Inc.
DatumRatingAnalyst
09.11.2016UnitedHealth Group NeutralMizuho
31.03.2011UnitedHealth Group performOppenheimer & Co. Inc.
08.02.2011UnitedHealth Group neutralGoldman Sachs Group Inc.
15.11.2010UnitedHealth Group holdStifel, Nicolaus & Co., Inc.
20.04.2010UnitedHealth neutralWedbush Morgan Securities Inc.
DatumRatingAnalyst
11.06.2009UnitedHealth underperformOppenheimer & Co. Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UnitedHealth Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"